New Pediatric Brain Cancer Biobank Aims to Accelerate Personalized Treatments
A groundbreaking biorepository has been established to tackle the scarcity of viable research material for pediatric brain cancer, the leading cause of cancer-related deaths in children. Led by Emon Nasajpour, MD, and his team, this pioneering biobank holds over 130 patient samples and mirrors the distribution of tumor subtypes in the US.
Nasajpour and colleagues, including Sumit Kumar, Matthew J. Love, and Michael J. Kennelly, created the biorepository containing viable cell dissociates and tissue from 39 distinct pediatric CNS tumor entities. They refined growth conditions to generate low-grade glioma models, validated using immunophenotyping and molecular profiling.
Analysis of RNA expression in a patient's pilocytic astrocytoma revealed distinct outliers. These were confirmed as potential drug targets in patient-matched cancer models. The biorepository demonstrates how patient-derived models can accelerate the discovery and validation of personalized treatment strategies for pediatric brain cancer.
The biorepository, containing samples from over 130 patients, mirrors the distribution of tumor subtypes reported in the Central Brain Tumor Registry of the United States. This effort underscores the potential of biobanking to transform pediatric neuro-oncology and bring hope to patients and families in urgent need.
Read also:
- Capella Nursing Students Gear Up for Crucial FPX 4050 Assessments
- Comprehensive Overview of Addressing Traumatic Brain Injuries (TBIs)
- Enhanced Health Services Provisioned by San Diego Academic Health Partnership Continues During COVID-19 and Beyond
- Vaccination drive targeting infants under 6 months old against bronchiolitis in the region of Andalucia
